BioSpace News Archive

Caris Life Sciences® announced today that the Herbert Irving Comprehensive Cancer Center (HICCC) has joined Caris’ Precision Oncology Alliance™ (POA).

Epizyme, Inc. today announced two appointments to the Company’s Board of Directors: clinical oncology executive, Roy A. Beveridge, M.D., and international pharmaceutical and financial executive, Carol Stuckley, M.B.A.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has announced it was named a winner in the MedReps.com Best Places to Work in Medical Sales 2022 survey, earning the Number 1 spot for large companies and making this the fifth consecutive year the company has been on the list.

If approved or authorized, PAXLOVID™ (PF-07321332; ritonavir) would be the first oral antiviral of its kind, a 3CL protease inhibitor specifically designed to combat SARS-CoV-2.

FDA Approves Merck’s KEYTRUDA ® (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery.

Applied Therapeutics, Inc. has announced a symposium and poster presentations at the 14th International Congress of Inborn Errors of Metabolism (ICIEM), November 21-23, 2021, Sydney, Australia.

Matinas BioPharma Holdings, Inc. has been invited to present a Company overview at the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29 – December 2, 2021.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), today announced that John H. Sampson, MD, PhD, MHSc, MBA, Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery at Duke University School of Medicine and member of Medicenna’s Board of Directors, received The Abstract Award for Excellence in Clinical Trials in connection with an upcoming oral presentation on MDNA55.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the data from the Phase 3 PROPEL pivotal trial, assessing the efficacy, safety and tolerability of AT-GAA in adults with late-onset Pompe disease compared to the standard of care, alglucosidase alfa, were published online in The Lancet Neurology.

CareDx, Inc. (Nasdaq: CDNA) – today announced the enrollment of the first patients in what will be the largest ever digital study measuring the impact of AlloCare™, a tech-enabled mobile health app, on organ transplant patient outcomes.